Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARGX-111 · 1 trial · 1 indication
Number of patients with grade 3 or 4 toxicity
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | ARGX-111 0.3 mg/kg |
| Arm 2 | EXPERIMENTAL | ARGX-111 1.0 mg/kg |
| Arm 3 | EXPERIMENTAL | ARGX-111 3.0 mg/kg |
| Arm 4 | EXPERIMENTAL | ARGX-111 10 mg/kg |
| Name | Type | Description |
|---|---|---|
| ARGX-111 | DRUG | - |
Inclusion Criteria: 1. Written informed consent. 2. Age ≥ 18 years. 3. Performance status of 0 or 1. 4. Histological diagnosis of malignancy. 5. Cancer relapsing after, or refractory to standard therapy. 6. Malignancy over-expressing the c Met protein. 7. Presence of circulating tumor cells (CTCs)....
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARGX-111 is an investigational small molecule being developed for the treatment of cancer. It is currently in Phase 1 clinical development, having completed a Phase 1b study in patients with advanced cancer. The drug is not yet approved and remains under investigation for its potential use in oncology.
ARGX-111 is being developed by argenx SE, a biopharmaceutical company traded on the stock exchange under the ticker ARGX. The company is conducting clinical research to evaluate the safety and efficacy of this investigational oncology drug.
ARGX-111 is in Phase 1 clinical development. A Phase 1b study of the drug in patients with advanced cancer has been completed. As an investigational agent, it has not yet received regulatory approval and is still in the early stages of clinical testing.
ARGX-111 has been studied in a single completed clinical trial, identified as NCT02055066. This was a Phase 1b study titled 'A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer,' which enrolled 24 participants in Belgium. The trial included adults aged 18 years and older.
ARGX-111 is not FDA approved. It is an investigational drug that has completed a Phase 1b clinical trial in advanced cancer patients. The drug remains in clinical development and has not yet been authorized for commercial use by regulatory authorities.